Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are male and aged 40 or older
- People who have been diagnosed with prostate cancer (adenocarcinoma type), confirmed by a tissue test
- People whose lymph nodes were found to be cancer-free, or whose lymph nodes could not be fully assessed, at the time of surgery
- People whose PSA level was below 0.1 ng/ml within 8 weeks after having their prostate surgically removed, and stayed at that level for at least 6 months
- People who have had a rise in PSA (two separate readings above 0.2 ng/ml, taken at least 2 weeks apart) after surgery, but where standard imaging scans (bone scan and CT/MRI) have not shown any cancer returning locally or spreading to other parts of the body
- People who are generally well and able to carry out daily activities with little or no limitation (confirm with trial site what this means for a specific situation)
- People with an estimated life expectancy of more than 10 years
- People whose blood and organ function tests (including blood cell counts, kidney function, liver function, and heart function) meet the required levels set by the trial
- People who are able to follow the trial schedule — one group would receive salvage radiation therapy, while the other group would be for people who are not suitable for or have declined radiation therapy
- People who have given their written agreement to take part
Who may not be able to join:
- People who have previously received hormone therapy (such as anti-androgens or medications that lower testosterone) or radiation therapy to the pelvic area
- People whose PSA level after surgery has risen above 2 ng/ml
- People whose post-surgery tissue analysis showed certain rare and aggressive cancer cell types (neuroendocrine or small cell features)
- People who have had another cancer (other than prostate cancer) within the past three years
- People with a history of seizures, or a known condition that may increase the risk of seizures
- People who have had serious heart or blood vessel problems — such as a heart attack, severe chest pain, heart failure, a blood clot (including pulmonary embolism), stroke, or significant heart rhythm problems — within the 6 months before joining
- People with an active ongoing infection such as HIV or viral hepatitis
- People who have any other serious or uncontrolled health condition that the trial doctor considers would make participation unsuitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Chief physician of Department of Urology, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phone: +86-13605171690
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
2-year biochemical progression-free survival; 3-year biochemical progression-free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.